The First Affiliated Hospital of Soochow University: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials

The registry lists 20 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with The First Affiliated Hospital of Soochow University as lead sponsor. 15 are open to participants now and 0 have results posted.

Early Phase 1 2Phase 1 3Phase 2 14Phase 3 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDSNot yet recruitingNCT07575412Phase 2
• SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDSNot yet recruitingNCT07562568Phase 2
• Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline ChemotherapyRecruitingNCT06985485Phase 2
• Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute LeukemiaRecruitingNCT06816134Phase 2
• Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic LeukemiaRecruitingNCT06696833Early Phase 1
• Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALLRecruitingNCT06578546Phase 2
• Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute LeukemiaNot yet recruitingNCT06559644Early Phase 1
• Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALLRecruitingNCT06393985Phase 2
• Haplo-cord HCT vs. Haplo-HCT for T-ALL PatientsRecruitingNCT06381817Phase 3
• CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).RecruitingNCT06078306Phase 2
• Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCTRecruitingNCT05809167Phase 2
• ThisCART19A Bridging to alloHSCT for R/R B-ALLRecruitingNCT05679687Phase 1
• CAV Regimen for R/R Ph- B-ALLRecruitingNCT05657652Not applicable
• Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALLRecruitingNCT05559450Phase 2
• Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）RecruitingNCT04534634Phase 2
• Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALLStatus unknownNCT05578378Phase 2/3
• Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsCompletedNCT05433532Phase 2
• Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers PatientsStatus unknownNCT04446130Phase 3
• CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic LeukemiaActive, not recruitingNCT03984968Phase 1/2
• CAR-T Cell Therapy Targeting to CD19 for R/R ALLActive, not recruitingNCT03919240Phase 1/2